Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Working towards a consensus on the oncological approach of breakthrough pain: a Delphi survey of Spanish experts.

Camps Herrero C, Antón Torres A, Cruz-Hernández JJ, Carrato A, Constenla M, Díaz-Rubio E, Feyjoo Saus M, Garcia-Foncillas J, Gascón P, Guillem V.

J Pain Res. 2019 Jul 29;12:2349-2358. doi: 10.2147/JPR.S203903. eCollection 2019.

2.

Correction: ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors.

Guerrero-Zotano AL, Stricker TP, Formisano L, Hutchinson KE, Stover DG, Lee KM, Schwarz LJ, Giltnane JM, Estrada MV, Jansen VM, Servetto A, Gavilá J, Perez-Fidalgo JA, Lluch A, Llombart-Cussac A, Bayar MA, Michiels S, André F, Arnedos M, Guillem V, Ruiz-Simon A, Arteaga CL.

Clin Cancer Res. 2019 Feb 15;25(4):1431. doi: 10.1158/1078-0432.CCR-18-4270. No abstract available.

3.

A novel predictive approach for GVHD after allogeneic SCT based on clinical variables and cytokine gene polymorphisms.

Martínez-Laperche C, Buces E, Aguilera-Morillo MC, Picornell A, González-Rivera M, Lillo R, Santos N, Martín-Antonio B, Guillem V, Nieto JB, González M, de la Cámara R, Brunet S, Jiménez-Velasco A, Espigado I, Vallejo C, Sampol A, Bellón JM, Serrano D, Kwon M, Gayoso J, Balsalobre P, Urbano-Izpizua Á, Solano C, Gallardo D, Díez-Martín JL, Romo J, Buño I; GVHD/Immunotherapy Committee of the Spanish Group for Hematopoietic Transplantation.

Blood Adv. 2018 Jul 24;2(14):1719-1737. doi: 10.1182/bloodadvances.2017011502.

4.

ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors.

Guerrero-Zotano AL, Stricker TP, Formisano L, Hutchinson KE, Stover DG, Lee KM, Schwarz LJ, Giltnane JM, Estrada MV, Jansen VM, Servetto A, Gavilá J, Perez-Fidalgo JA, Lluch A, Llombart-Cussac A, Bayar MA, Michiels S, André F, Arnedos M, Guillem V, Ruiz-Simon A, Arteaga CL.

Clin Cancer Res. 2018 Jun 1;24(11):2517-2529. doi: 10.1158/1078-0432.CCR-17-2904. Epub 2018 Mar 26. Erratum in: Clin Cancer Res. 2019 Feb 15;25(4):1431.

5.

Bone marrow VEGFC expression is associated with multilineage dysplasia and several prognostic markers in adult acute myeloid leukemia, but not with survival.

Guillem V, Calabuig M, Brunet S, Esteve J, Escoda L, Gallardo D, Ribera JM, Queipo de Llano MP, Arnan M, Pedro C, Amigo ML, Martí-Tutusaus JM, García-Guiñón A, Bargay J, Sampol A, Salamero O, Font L, Talarn C, Hoyos M, Díaz-Beyá M, Garrido A, Navarro B, Nomdédeu J, Sierra J, Tormo M.

Leuk Lymphoma. 2018 Oct;59(10):2383-2393. doi: 10.1080/10428194.2017.1422858. Epub 2018 Jan 18.

PMID:
29345176
6.

Association of RBP4 genetic variants with childhood obesity and cardiovascular risk factors.

Codoñer-Franch P, Carrasco-Luna J, Allepuz P, Codoñer-Alejos A, Guillem V.

Pediatr Diabetes. 2016 Dec;17(8):576-583. doi: 10.1111/pedi.12339. Epub 2015 Nov 26.

7.

European edition of the NCCN clinical practice guidelines: relevance of the translation and adaptation into Spanish.

Guillem V, Camps C, Carrato A, Díaz-Rubio E, Gascón P.

Clin Transl Oncol. 2017 Mar;19(3):288-290. doi: 10.1007/s12094-016-1545-6. Epub 2016 Sep 7.

PMID:
27604422
8.

Evaluating the Applicability of Data-Driven Dietary Patterns to Independent Samples with a Focus on Measurement Tools for Pattern Similarity.

Castelló A, Buijsse B, Martín M, Ruiz A, Casas AM, Baena-Cañada JM, Pastor-Barriuso R, Antolín S, Ramos M, Muñoz M, Lluch A, de Juan-Ferré A, Jara C, Lope V, Jimeno MA, Arriola-Arellano E, Díaz E, Guillem V, Carrasco E, Pérez-Gómez B, Vioque J, Pollán M; GEICAM researchers.

J Acad Nutr Diet. 2016 Dec;116(12):1914-1924.e6. doi: 10.1016/j.jand.2016.05.008. Epub 2016 Jun 28.

PMID:
27373727
9.

Quality Indicators to Assure and Improve Cancer Care in Spain Using the Delphi Technique.

Camps C, Albanell J, Antón A, Aranda E, Carrato A, Cassinello J, Castellano D, Cruz JJ, Garrido P, Guillem V, Grávalos C, López G, Llorente C, Lorenzo A, Lluch A, Ignacio E, Díaz-Rubio E.

J Natl Compr Canc Netw. 2016 May;14(5):553-8.

PMID:
27160233
10.

Treatment patterns of adjuvant interferon-α2b for high-risk melanoma: a retrospective study of the Grupo Español Multidisciplinar de Melanoma - Prima study.

Espinosa E, Soriano V, Malvehy J, Berrocal A, Martínez de Prado P, Quindós M, Soria A, Márquez-Rodas I, Palacio I, Cerezuela P, López-Vivanco G, Alonso L, Samaniego E, Ballesteros A, Puértolas T, Díaz-Beveridge R, de la Cruz-Merino L, López Castro R, López López R, Stevinson K, Del Barrio P, Tornamira MV, Guillém V, Martín-Algarra S.

Melanoma Res. 2016 Jun;26(3):278-83. doi: 10.1097/CMR.0000000000000254.

11.

The Genotype of the Donor for the (GT)n Polymorphism in the Promoter/Enhancer of FOXP3 Is Associated with the Development of Severe Acute GVHD but Does Not Affect the GVL Effect after Myeloablative HLA-Identical Allogeneic Stem Cell Transplantation.

Noriega V, Martínez-Laperche C, Buces E, Pion M, Sánchez-Hernández N, Martín-Antonio B, Guillem V, Bosch-Vizcaya A, Bento L, González-Rivera M, Balsalobre P, Kwon M, Serrano D, Gayoso J, de la Cámara R, Brunet S, Rojas-Contreras R, Nieto JB, Martínez C, Gónzalez M, Espigado I, Vallejo JC, Sampol A, Jiménez-Velasco A, Urbano-Ispizua A, Solano C, Gallardo D, Díez-Martín JL, Buño I; Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH).

PLoS One. 2015 Oct 16;10(10):e0140454. doi: 10.1371/journal.pone.0140454. eCollection 2015.

12.

BCL2 gene polymorphisms and splicing variants in chronic myeloid leukemia.

Guillem V, Amat P, Collado M, Cervantes F, Alvarez-Larrán A, Martínez J, Tormo E, Eroles P, Solano C, Hernández-Boluda JC.

Leuk Res. 2015 Aug 28. pii: S0145-2126(15)30367-2. doi: 10.1016/j.leukres.2015.08.014. [Epub ahead of print]

PMID:
26344465
13.

Risk factors for non-melanoma skin cancer in patients with essential thrombocythemia and polycythemia vera.

Gómez M, Guillem V, Pereira A, Ferrer-Marín F, Álvarez-Larrán A, Kerguelen A, Estrada N, Martínez-López J, Angona A, Amat P, Navarro B, Besses C, Hernández-Boluda JC.

Eur J Haematol. 2016 Mar;96(3):285-90. doi: 10.1111/ejh.12588. Epub 2015 Jun 9.

PMID:
25996073
14.

Lower Breast Cancer Risk among Women following the World Cancer Research Fund and American Institute for Cancer Research Lifestyle Recommendations: EpiGEICAM Case-Control Study.

Castelló A, Martín M, Ruiz A, Casas AM, Baena-Cañada JM, Lope V, Antolín S, Sánchez P, Ramos M, Antón A, Muñoz M, Bermejo B, De Juan-Ferré A, Jara C, Chacón JI, Jimeno MA, Rosado P, Díaz E, Guillem V, Lluch A, Carrasco E, Pérez-Gómez B, Vioque J, Pollán M; EpiGEICAM Researchers.

PLoS One. 2015 May 15;10(5):e0126096. doi: 10.1371/journal.pone.0126096. eCollection 2015.

15.

Controversies in the treatment of invasive urothelial carcinoma: a case report and review of the literature.

Guillem V, Climent MA, Cassinello J, Esteban E, Castellano D, González-Larriba JL, Maroto P, Camps C.

BMC Urol. 2015 Mar 13;15:15. doi: 10.1186/s12894-015-0008-7. Review.

16.

Spanish Mediterranean diet and other dietary patterns and breast cancer risk: case-control EpiGEICAM study.

Castelló A, Pollán M, Buijsse B, Ruiz A, Casas AM, Baena-Cañada JM, Lope V, Antolín S, Ramos M, Muñoz M, Lluch A, de Juan-Ferré A, Jara C, Jimeno MA, Rosado P, Díaz E, Guillem V, Carrasco E, Pérez-Gómez B, Vioque J, Boeing H, Martín M; GEICAM researchers.

Br J Cancer. 2014 Sep 23;111(7):1454-62. doi: 10.1038/bjc.2014.434. Epub 2014 Aug 7.

17.

Efficacy and safety of neoadjuvant chemotherapy with concurrent liposomal-encapsulated doxorubicin, paclitaxel and trastuzumab for human epidermal growth factor receptor 2-positive breast cancer in clinical practice.

Gavilá J, Guerrero Á, Climent MÁ, Fernández A, Gozalbo F, Carrascosa M, Camps J, Guillem V, Ruiz A.

Int J Clin Oncol. 2015 Jun;20(3):480-9. doi: 10.1007/s10147-014-0727-x. Epub 2014 Jul 11.

PMID:
25011497
18.

Oncological translational research in the Spanish national health system: the INTRO study.

Caballero C, Jantus-Lewintre E, Carrato A, García-Foncillas J, Gascón P, Blasco A, Moreno-Nogueira JA, Guillem V, López R, Codes M, Antón A, Díaz-Rubio E, Camps C.

Clin Transl Oncol. 2014 Aug;16(8):686-95. doi: 10.1007/s12094-013-1138-6. Epub 2013 Dec 5.

PMID:
24307394
19.

A polymorphism in the TYMP gene is associated with the outcome of HLA-identical sibling allogeneic stem cell transplantation.

Guillem V, Hernández-Boluda JC, Gallardo D, Buño I, Bosch A, Martínez-Laperche C, de la Cámara R, Brunet S, Martin C, Nieto JB, Martínez C, Pérez A, Montoro J, Garcia-Noblejas A, Solano C; Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH).

Am J Hematol. 2013 Oct;88(10):883-9. doi: 10.1002/ajh.23523. Epub 2013 Aug 1.

20.

Incidence and predictors of ovarian function recovery (OFR) in breast cancer (BC) patients with chemotherapy-induced amenorrhea (CIA) who switched from tamoxifen to exemestane.

Guerrero A, Gavilá J, Folkerd E, Ortiz B, Martínez F, García A, Climent MA, Guillem V, Ruíz A.

Ann Oncol. 2013 Mar;24(3):674-9. doi: 10.1093/annonc/mds464. Epub 2012 Oct 28.

PMID:
23108951
21.

A polymorphism in the XPD gene predisposes to leukemic transformation and new nonmyeloid malignancies in essential thrombocythemia and polycythemia vera.

Hernández-Boluda JC, Pereira A, Cervantes F, Alvarez-Larrán A, Collado M, Such E, Arilla MJ, Boqué C, Xicoy B, Maffioli M, Bellosillo B, Marugán I, Amat P, Besses C, Guillem V.

Blood. 2012 May 31;119(22):5221-8. doi: 10.1182/blood-2012-02-411215. Epub 2012 Apr 11.

22.

APC and KRAS mutations in distal colorectal polyps are related to smoking habits in men: results of a cross-sectional study.

Martínez F, Fernández-Martos C, Quintana MJ, Castells A, Llombart A, Ińiguez F, Guillem V, Dasí F.

Clin Transl Oncol. 2011 Sep;13(9):664-71. doi: 10.1007/s12094-011-0712-z.

PMID:
21865138
23.

Functional polymorphisms in SOCS1 and PTPN22 genes correlate with the response to imatinib treatment in newly diagnosed chronic-phase chronic myeloid leukemia.

Guillem V, Amat P, Cervantes F, Alvarez-Larrán A, Cervera J, Maffioli M, Bellosillo B, Collado M, Marugán I, Martínez-Ruiz F, Hernández-Boluda JC.

Leuk Res. 2012 Feb;36(2):174-81. doi: 10.1016/j.leukres.2011.06.011. Epub 2011 Jul 2.

PMID:
21724255
24.

Donor CTLA-4 genotype influences clinical outcome after T cell-depleted allogeneic hematopoietic stem cell transplantation from HLA-identical sibling donors.

Bosch-Vizcaya A, Pérez-García A, Brunet S, Solano C, Buño I, Guillem V, Martínez-Laperche C, Sanz G, Barrenetxea C, Martínez C, Tuset E, Lloveras N, Coll R, Guardia R, González Y, Roncero JM, Bustins A, Gardella S, Fernández C, Buch J, Gallardo D; GvHD/Immunotherapy committee of the Spanish Group for Hematopoietic Transplant (GETH).

Biol Blood Marrow Transplant. 2012 Jan;18(1):100-5. doi: 10.1016/j.bbmt.2011.05.021. Epub 2011 Jun 12.

25.

An XRCC1 polymorphism is associated with the outcome of patients with lymphoma undergoing autologous stem cell transplant.

Guillem VM, Arbona C, Hernández-Boluda JC, Terol MJ, Goterris R, Solano C, Tormo M.

Leuk Lymphoma. 2011 Jul;52(7):1249-54. doi: 10.3109/10428194.2011.564694. Epub 2011 Apr 4.

PMID:
21463129
26.

Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia.

Maffioli M, Camós M, Gaya A, Hernández-Boluda JC, Alvarez-Larrán A, Domingo A, Granell M, Guillem V, Vallansot R, Costa D, Bellosillo B, Colomer D, Cervantes F.

Leuk Res. 2011 Aug;35(8):1014-9. doi: 10.1016/j.leukres.2010.12.004. Epub 2010 Dec 24.

PMID:
21185600
27.

A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01.

Bellmunt J, Maroto-Rey P, Trigo JM, Carles J, Guillem V, López-Martín JA, Antón-Torres A, Urruticoechea L.

Clin Transl Oncol. 2010 Jul;12(7):503-8. doi: 10.1007/s12094-010-0544-2.

PMID:
20615828
28.

Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation.

Porta R, Sánchez-Torres JM, Paz-Ares L, Massutí B, Reguart N, Mayo C, Lianes P, Queralt C, Guillem V, Salinas P, Catot S, Isla D, Pradas A, Gúrpide A, de Castro J, Polo E, Puig T, Tarón M, Colomer R, Rosell R.

Eur Respir J. 2011 Mar;37(3):624-31. doi: 10.1183/09031936.00195609. Epub 2010 Jul 1.

29.

XPC genetic polymorphisms correlate with the response to imatinib treatment in patients with chronic phase chronic myeloid leukemia.

Guillem VM, Cervantes F, Martínez J, Alvarez-Larrán A, Collado M, Camós M, Sureda A, Maffioli M, Marugán I, Hernández-Boluda JC.

Am J Hematol. 2010 Jul;85(7):482-6. doi: 10.1002/ajh.21726.

30.

A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole.

Garcia-Casado Z, Guerrero-Zotano A, Llombart-Cussac A, Calatrava A, Fernandez-Serra A, Ruiz-Simon A, Gavila J, Climent MA, Almenar S, Cervera-Deval J, Campos J, Albaladejo CV, Llombart-Bosch A, Guillem V, Lopez-Guerrero JA.

BMC Cancer. 2010 Feb 9;10:36. doi: 10.1186/1471-2407-10-36.

31.

Phase II randomized study of Plitidepsin (Aplidin), alone or in association with L-carnitine, in patients with unresectable advanced renal cell carcinoma.

Schöffski P, Guillem V, Garcia M, Rivera F, Tabernero J, Cullell M, Lopez-Martin JA, Pollard P, Dumez H, del Muro XG, Paz-Ares L.

Mar Drugs. 2009;7(1):57-70. doi: 10.3390/md7010057. Epub 2009 Mar 5.

32.

Optimizing treatment for men with advanced prostate cancer: expert recommendations and the multidisciplinary approach.

Fitzpatrick JM, Anderson J, Sternberg CN, Fleshner N, Fizazi K, Rébillard X, Dogliotti L, Conti G, Turesson I, James N, Heidenreich A, Solsona E, Guillem V, Herchenhorn D, Moul J, van Moorselaar J, Coetzee LJ, Wilson A, Bamias A, De Wit R, Chrisofos M.

Crit Rev Oncol Hematol. 2008 Oct;68 Suppl 1:S9-S22. doi: 10.1016/j.critrevonc.2008.07.019. Epub 2008 Aug 23. Review.

PMID:
18723368
33.

Influence of DNA damage and repair upon the risk of treatment related leukemia.

Guillem V, Tormo M.

Leuk Lymphoma. 2008 Feb;49(2):204-17. doi: 10.1080/10428190701769657. Review.

PMID:
18231906
34.

Invasive fungal infection and nasal septum perforation with bevacizumab-based therapy in advanced colon cancer.

Ruiz N, Fernandez-Martos C, Romero I, Pla A, Maiquez J, Calatrava A, Guillem V.

J Clin Oncol. 2007 Aug 1;25(22):3376-7. No abstract available.

PMID:
17664487
35.

Role of MTHFR (677, 1298) haplotype in the risk of developing secondary leukemia after treatment of breast cancer and hematological malignancies.

Guillem VM, Collado M, Terol MJ, Calasanz MJ, Esteve J, Gonzalez M, Sanzo C, Nomdedeu J, Bolufer P, Lluch A, Tormo M.

Leukemia. 2007 Jul;21(7):1413-22. Epub 2007 May 3.

PMID:
17476281
36.

Germ cell tumours of the ovary.

Guillem V, Poveda A.

Clin Transl Oncol. 2007 Apr;9(4):237-43. Review.

PMID:
17462976
37.

Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial.

Martín M, Ruiz A, Muñoz M, Balil A, García-Mata J, Calvo L, Carrasco E, Mahillo E, Casado A, García-Saenz JA, Escudero MJ, Guillem V, Jara C, Ribelles N, Salas F, Soto C, Morales-Vasquez F, Rodríguez CA, Adrover E, Mel JR; Spanish Breast Cancer Research Group (GEICAM) trial.

Lancet Oncol. 2007 Mar;8(3):219-25.

PMID:
17329192
38.

[One year follow up of successful coronary angioplasty in non selected patients].

Dighero T H, Wajner A J, Puentes R A, Zepeda M F, Bellet P A, Donoso P H, Guillem V A, Aranda C W.

Rev Med Chil. 2006 Nov;134(11):1383-92. Epub 2007 Jan 2. Spanish.

39.

Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.

Bellmunt J, Paz-Ares L, Cuello M, Cecere FL, Albiol S, Guillem V, Gallardo E, Carles J, Mendez P, de la Cruz JJ, Taron M, Rosell R, Baselga J; Spanish Oncology Genitourinary Group.

Ann Oncol. 2007 Mar;18(3):522-8. Epub 2007 Jan 17.

PMID:
17229776
40.

Clinical practice guidelines on antiemetics in oncology.

Aranda Aguilar E, Constenla Figueiras M, Cortes-Funes H, Diaz-Rubio García E, Gascon Vilaplana P, Guillém V, Martin-Algarra S.

Expert Rev Anticancer Ther. 2005 Dec;5(6):963-72. Review.

PMID:
16336087
41.

Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer.

Baselga J, Albanell J, Ruiz A, Lluch A, Gascón P, Guillém V, González S, Sauleda S, Marimón I, Tabernero JM, Koehler MT, Rojo F.

J Clin Oncol. 2005 Aug 10;23(23):5323-33. Epub 2005 Jun 6.

PMID:
15939921
42.

A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer.

Tabernero J, Climent MA, Lluch A, Albanell J, Vermorken JB, Barnadas A, Antón A, Laurent C, Mayordomo JI, Estaun N, Losa I, Guillem V, Garcia-Conde J, Tisaire JL, Baselga J.

Ann Oncol. 2004 Sep;15(9):1358-65.

PMID:
15319242
43.

Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domain.

Colomer R, Llombart-Cussac A, Lluch A, Barnadas A, Ojeda B, Carañana V, Fernández Y, García-Conde J, Alonso S, Montero S, Hornedo J, Guillem V.

Ann Oncol. 2004 Feb;15(2):201-6.

PMID:
14760109
44.

Activity and safety of oxaliplatin with weekly 5-fluorouracil bolus and low-dose leucovorin as first-line treatment for advanced colorectal cancer.

Cassinello J, Escudero P, Salud A, Marcos F, Pujol E, Pérez-Carrión R, Colmenarejo A, González del Val R, Valero J, Oruezábal MJ, Guillem V, García I, Arcediano A, Marfà X.

Clin Colorectal Cancer. 2003 Aug;3(2):108-12.

PMID:
12952567
45.

A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy.

Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, Siena S, Lalisang RI, Samonigg H, Clemens MR, Zani V, Liang BC, Renwick J, Piccart MJ; International Pegfilgrastim 749 Study Group.

Ann Oncol. 2003 Jan;14(1):29-35.

PMID:
12488289
46.

Targeted oligonucleotide delivery in human lymphoma cell lines using a polyethyleneimine based immunopolyplex.

Guillem VM, Tormo M, Moret I, Benet I, García-Conde J, Crespo A, Aliño SF.

J Control Release. 2002 Sep 18;83(1):133-46.

PMID:
12220845
47.

Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine.

Bellmunt J, Albanell J, Paz-Ares L, Climent MA, González-Larriba JL, Carles J, de la Cruz JJ, Guillem V, Díaz-Rubio E, Cortés-Funes H, Baselga J; Spanish Oncology Genitourinary Group.

Cancer. 2002 Aug 15;95(4):751-7.

48.

Polyethyleneimine-based immunopolyplex for targeted gene transfer in human lymphoma cell lines.

Guillem VM, Tormo M, Revert F, Benet I, García-Conde J, Crespo A, Aliño SF.

J Gene Med. 2002 Mar-Apr;4(2):170-82.

PMID:
11933218
49.

Stability of PEI-DNA and DOTAP-DNA complexes: effect of alkaline pH, heparin and serum.

Moret I, Esteban Peris J, Guillem VM, Benet M, Revert F, Dasí F, Crespo A, Aliño SF.

J Control Release. 2001 Sep 11;76(1-2):169-81.

PMID:
11532322
50.

[Experience in the treatment of 98 carcinomas of the nasopharynx. Long-term follow-up and analysis of prognostic factors].

Gaspar C, Zapater E, Chust M, Climent MA, Ferrándis E, Muñoz MA, Mengual JL, Berrocal A, Vendrell BJ, Arribas L, Guillem V.

Acta Otorrinolaringol Esp. 2000 Nov-Dec;51(8):691-6. Spanish.

PMID:
11270103

Supplemental Content

Loading ...
Support Center